When was Blue Rock Therapeutics founded?

Blue Rock Therapeutics was founded in 2016 and raised its 1st funding round within a year of its incorporation.

Where is Blue Rock Therapeutics located?

Blue Rock Therapeutics is headquartered in Boston, United States. It is registered at Cambridge, Massachusetts.

How many employees does Blue Rock Therapeutics have?

As of Mar 31, 2026, the latest employee count at Blue Rock Therapeutics is 459.

Is Blue Rock Therapeutics a funded company?

Blue Rock Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Dec 12, 2016.

How much is Blue Rock Therapeutics worth?

The last known valuation of Blue Rock Therapeutics was $***** as of Aug 08, 2019.

When was the latest funding round of Blue Rock Therapeutics?

Blue Rock Therapeutics' latest funding was a $***** Series A round on Dec 12, 2016, with participation from 2 investors.

Where does Blue Rock Therapeutics rank among its competitors?

Blue Rock Therapeutics ranks 12th amongst 629 active competitors, of which 207 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was PAQ, which secured $38M in Jan, 2026.

Who are the top competitors of Blue Rock Therapeutics?

Blue Rock Therapeutics' top competitors include Alector, Juvenescence and Annexon. Among them, PAQ secured the most recent funding round in January, 2026.

Blue Rock Therapeutics - 2026 Company Profile, Funding & Competitors

Blue Rock Therapeutics is an acquired company based in Boston (United States), founded in 2016. It operates as a Stem cell therapies for cardiovascular and neurological diseases. Blue Rock Therapeutics has raised $225M in funding from Versant Ventures and Leaps by Bayer, with last known valuation of $*****. The company has 629 active competitors, including 207 funded and 96 that have exited. Its top competitors include companies like Alector, Juvenescence and Annexon.

Company Details

Stem cell therapies for cardiovascular and neurological diseases. It is focused on developing stem cell therapeutics for the treatment of cardiovascular, neurological diseases. Its lead stem cell program is to regenerate heart muscle in patients who have had a heart attack or are suffering from chronic heart failure.

Website: bluerocktx.com
Social
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2016

Location

Boston, United States

Stage

Acquired

Total Funding

$225M in 1 round

Latest Funding Round

Series A, Dec 12, 2016, $*****

Last Known Valuation

$***** as on Aug 08, 2019

Investors

Versant Ventures & 2 more

Ranked

12^th among 629 active competitors

Employee Count

459 as on Mar 31, 2026

Similar Companies

Alector & 616 more

Exit Details

Acquired by Leaps by Bayer (Aug 08, 2019)

View Blue Rock Therapeutics' full profile

Blue Rock Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Bluerock Therapeutics Lp CIN: 364841934 , United States, Active	Dec 26, 999	-	232 (As on Dec 31, 2024)	-

Blue Rock Therapeutics got acquired by Leaps by Bayer on Aug 08, 2019 at an acquisition amount of $600M.

Click here to take a look at Blue Rock Therapeutics's acquisition in detail

Blue Rock Therapeutics has raised a total funding of $225M over 1 round. Its latest funding round was a Series A round on Dec 12, 2016 for $*****. 2 investors participated in its latest round. Blue Rock Therapeutics has 3 institutional investors.

Here is the list of recent funding rounds of Blue Rock Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 12, 2016	5352425	Series A	5685330	3591823	9228480	6181479

Access funding benchmarks and valuations. Sign up today!

View details of Blue Rock Therapeutics's funding rounds and investors

Blue Rock Therapeutics' employee count trend

Blue Rock Therapeutics has 459 employees as of Mar 26. Here is Blue Rock Therapeutics's employee count trend over the years:

Employee count trend for Blue Rock Therapeutics

Uncover Blue Rock Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Blue Rock Therapeutics include Alector, Juvenescence and Annexon. Here is the list of Top 10 competitors of Blue Rock Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	72/100
2nd	Juvenescence 2017, Dublin (Ireland), Series B	Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health	$290M	Ipgl, Foresite Capital & 9 others	68/100
3rd	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, New Enterprise Associates ... & 16 others	67/100
4th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, Sanofi & 5 others	65/100
5th	Aspen Neuroscience 2018, San Diego (United States), Series C	Provider of genomic-based personalised pluripotent stem cell therapy	$339M	Revelation Partners, Orbimed & 22 others	65/100
6th	Axsome Therapeutics 2012, New York City (United States), Public	Developer of therapeutic solutions for the management of CNS disorders	$8.7M	SVB Securities, Collage Venture Partners	65/100
7th	Amphista Therapeutics 2018, Motherwell (United Kingdom), Series B	Developer of targeted protein degradation technology-based therapeutics	$60.5M	Advent Life Sciences, Gilde Healthcare & 10 others	64/100
8th	PAQ 2020, Cambridge (United States), Series B	Developer of small molecule therapeutics for neurodegenerative disease	$111M	MRLV, Sherpa Healthcare Partners & 8 others	63/100
9th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Small molecule drugs that target deubiquitylating enzymes involved in the DNA damage response	$192M	Pfizer Venture Investments, Sofinnova Partners ... & 46 others	63/100
10th	US World Meds 2001, Louisville (United States), Series B	Developer of therapeutics for the treatment of multiple diseases	$149M	Athyrium Capital Management, CRG & 5 others	63/100
12th	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, JLABS & 1 others	62/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Blue Rock Therapeutics's competitors? Click here to see the top ones

Blue Rock Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Blue Rock Therapeutics's sector:

Free

Diversified Pharmaceuticals - Sector Report

Edition: October, 2025 (57 Pages)

View all reports related to Blue Rock Therapeutics

Media has covered Blue Rock Therapeutics for a total of 7 events in the last 1 year, 4 of them have been about company updates and 1 about people movement.